Zymeworks (FRA:ZA8) ROE % Adjusted to Book Value : -16.83% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Zymeworks ROE % Adjusted to Book Value?

Zymeworks's ROE % for the quarter that ended in Mar. 2024 was -28.10%. Zymeworks's PB Ratio for the quarter that ended in Mar. 2024 was 1.67. Zymeworks's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -16.83%.

Zymeworks ROE % Adjusted to Book Value Historical Data

The historical data trend for Zymeworks's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks ROE % Adjusted to Book Value Chart

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-9.44

-10.39

-24.37

35.29

-15.65

Zymeworks Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-15.91	-34.99	-26.75	-8.27	-16.83

Competitive Comparison of Zymeworks's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Zymeworks's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Zymeworks's ROE % Adjusted to Book Value falls into.

Zymeworks ROE % Adjusted to Book Value Calculation

Zymeworks's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-24.41%	/	1.56
	=	-15.65%

Zymeworks's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-28.10%	/	1.67
	=	-16.83%

Zymeworks ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Zymeworks's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (FRA:ZA8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ZYME:USA

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks (FRA:ZA8) Headlines

No Headlines